Cargando…

Metabolic Dysregulation and Psychosocial Stress in Patients with Schizophrenia Spectrum Disorders: A Case-Control Study

Patients with schizophrenia spectrum disorders have a reduced life expectancy, which is largely the consequence of a high co-occurrence of cardiovascular diseases. To date, several intrinsic and environmental factors underlying this phenomenon have been found. However, the association with psychosoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Misiak, Błażej, Piotrowski, Patryk, Beszłej, Jan Aleksander, Kalinowska, Sylwia, Chęć, Magdalena, Samochowiec, Jerzy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760156/
https://www.ncbi.nlm.nih.gov/pubmed/33255883
http://dx.doi.org/10.3390/jcm9123822
_version_ 1783627266613313536
author Misiak, Błażej
Piotrowski, Patryk
Beszłej, Jan Aleksander
Kalinowska, Sylwia
Chęć, Magdalena
Samochowiec, Jerzy
author_facet Misiak, Błażej
Piotrowski, Patryk
Beszłej, Jan Aleksander
Kalinowska, Sylwia
Chęć, Magdalena
Samochowiec, Jerzy
author_sort Misiak, Błażej
collection PubMed
description Patients with schizophrenia spectrum disorders have a reduced life expectancy, which is largely the consequence of a high co-occurrence of cardiovascular diseases. To date, several intrinsic and environmental factors underlying this phenomenon have been found. However, the association with psychosocial stress has not been extensively addressed. In this study, we tested the relationship between a history of adverse childhood experiences (ACEs), lifetime stressors, perceived stress and metabolic parameters in patients with schizophrenia spectrum disorders and in healthy controls. The participants included 85 inpatients with schizophrenia spectrum disorders and 56 healthy controls. Serum levels of glucose, insulin, low- and high-density lipoproteins (LDL and HDL), triglycerides, total cholesterol and high-sensitivity C-reactive protein (hsCRP) were determined. After adjustment for potential confounding factors, patients had significantly higher levels of glucose (F = 4.856, p = 0.030), triglycerides (F = 4.720, p = 0.032) and hsCRP (F = 7.499, p = 0.007) as well as significantly lower levels of HDL (F = 5.300, p = 0.023) compared to healthy controls. There were also significant effects of interactions between diagnosis and a history of ACEs on the levels of insulin (F = 4.497, p = 0.036) and homeostatic model assessment of insulin resistance (HOMA-IR) (F = 3.987, p = 0.048). More specifically, the levels of insulin and HOMA-IR were significantly higher in the subgroup of patients with schizophrenia spectrum disorders and a positive history of ACEs compared to other subgroups of participants. No significant associations between lifetime stressors and perceived stress with metabolic parameters were found. Our findings indicate that a history of ACEs might be associated with insulin resistance in patients with schizophrenia spectrum disorders. Therapeutic strategies targeting early-life stress should be considered with early interventions that aim to manage cardiometabolic comorbidity in patients with schizophrenia spectrum disorders.
format Online
Article
Text
id pubmed-7760156
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77601562020-12-26 Metabolic Dysregulation and Psychosocial Stress in Patients with Schizophrenia Spectrum Disorders: A Case-Control Study Misiak, Błażej Piotrowski, Patryk Beszłej, Jan Aleksander Kalinowska, Sylwia Chęć, Magdalena Samochowiec, Jerzy J Clin Med Article Patients with schizophrenia spectrum disorders have a reduced life expectancy, which is largely the consequence of a high co-occurrence of cardiovascular diseases. To date, several intrinsic and environmental factors underlying this phenomenon have been found. However, the association with psychosocial stress has not been extensively addressed. In this study, we tested the relationship between a history of adverse childhood experiences (ACEs), lifetime stressors, perceived stress and metabolic parameters in patients with schizophrenia spectrum disorders and in healthy controls. The participants included 85 inpatients with schizophrenia spectrum disorders and 56 healthy controls. Serum levels of glucose, insulin, low- and high-density lipoproteins (LDL and HDL), triglycerides, total cholesterol and high-sensitivity C-reactive protein (hsCRP) were determined. After adjustment for potential confounding factors, patients had significantly higher levels of glucose (F = 4.856, p = 0.030), triglycerides (F = 4.720, p = 0.032) and hsCRP (F = 7.499, p = 0.007) as well as significantly lower levels of HDL (F = 5.300, p = 0.023) compared to healthy controls. There were also significant effects of interactions between diagnosis and a history of ACEs on the levels of insulin (F = 4.497, p = 0.036) and homeostatic model assessment of insulin resistance (HOMA-IR) (F = 3.987, p = 0.048). More specifically, the levels of insulin and HOMA-IR were significantly higher in the subgroup of patients with schizophrenia spectrum disorders and a positive history of ACEs compared to other subgroups of participants. No significant associations between lifetime stressors and perceived stress with metabolic parameters were found. Our findings indicate that a history of ACEs might be associated with insulin resistance in patients with schizophrenia spectrum disorders. Therapeutic strategies targeting early-life stress should be considered with early interventions that aim to manage cardiometabolic comorbidity in patients with schizophrenia spectrum disorders. MDPI 2020-11-26 /pmc/articles/PMC7760156/ /pubmed/33255883 http://dx.doi.org/10.3390/jcm9123822 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Misiak, Błażej
Piotrowski, Patryk
Beszłej, Jan Aleksander
Kalinowska, Sylwia
Chęć, Magdalena
Samochowiec, Jerzy
Metabolic Dysregulation and Psychosocial Stress in Patients with Schizophrenia Spectrum Disorders: A Case-Control Study
title Metabolic Dysregulation and Psychosocial Stress in Patients with Schizophrenia Spectrum Disorders: A Case-Control Study
title_full Metabolic Dysregulation and Psychosocial Stress in Patients with Schizophrenia Spectrum Disorders: A Case-Control Study
title_fullStr Metabolic Dysregulation and Psychosocial Stress in Patients with Schizophrenia Spectrum Disorders: A Case-Control Study
title_full_unstemmed Metabolic Dysregulation and Psychosocial Stress in Patients with Schizophrenia Spectrum Disorders: A Case-Control Study
title_short Metabolic Dysregulation and Psychosocial Stress in Patients with Schizophrenia Spectrum Disorders: A Case-Control Study
title_sort metabolic dysregulation and psychosocial stress in patients with schizophrenia spectrum disorders: a case-control study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760156/
https://www.ncbi.nlm.nih.gov/pubmed/33255883
http://dx.doi.org/10.3390/jcm9123822
work_keys_str_mv AT misiakbłazej metabolicdysregulationandpsychosocialstressinpatientswithschizophreniaspectrumdisordersacasecontrolstudy
AT piotrowskipatryk metabolicdysregulationandpsychosocialstressinpatientswithschizophreniaspectrumdisordersacasecontrolstudy
AT beszłejjanaleksander metabolicdysregulationandpsychosocialstressinpatientswithschizophreniaspectrumdisordersacasecontrolstudy
AT kalinowskasylwia metabolicdysregulationandpsychosocialstressinpatientswithschizophreniaspectrumdisordersacasecontrolstudy
AT checmagdalena metabolicdysregulationandpsychosocialstressinpatientswithschizophreniaspectrumdisordersacasecontrolstudy
AT samochowiecjerzy metabolicdysregulationandpsychosocialstressinpatientswithschizophreniaspectrumdisordersacasecontrolstudy